6533b85dfe1ef96bd12bdd7a

RESEARCH PRODUCT

Focal nodular hyperplasia: a weight-based, intraindividual comparison of gadobenate dimeglumine and gadoxetate disodium-enhanced MRI

Massimo MidiriDomenica MatrangaRoberto LagallaAdele TaibbiGiuseppe BrancatelliTommaso Vincenzo Bartolotta

subject

AdultGadolinium DTPAMaleContrast MediaLiver MRI neoplasm030218 nuclear medicine & medical imagingGadoxetate DisodiumLesion03 medical and health sciences0302 clinical medicineMcNemar's testMegluminemedicineOrganometallic CompoundsHumansRadiology Nuclear Medicine and imagingIntraindividual comparisonAbdominal ImagingGADOBENATE DIMEGLUMINERetrospective Studiesmedicine.diagnostic_testbusiness.industryLiver NeoplasmsFocal nodular hyperplasiaMagnetic resonance imagingMiddle Agedmedicine.diseaseImage EnhancementMagnetic Resonance ImagingLiverEvaluation Studies as TopicFocal Nodular HyperplasiaFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessNuclear medicineSettore MED/36 - Diagnostica Per Immagini E RadioterapiaWeight based dosing

description

PURPOSE: We aimed to qualitatively and quantitatively compare the enhancement pattern of focal nodular hyperplasia after gadobenate dimeglumine and gadoxetate disodium injection in the same patient. METHODS: 1.5 T magnetic resonance imaging (MRI) examinations of 16 patients with 21 focal nodular hyperplasias studied after the injection of both contrast media were evaluated. Both MRI studies were performed in all patients. A qualitative analysis was performed evaluating each lesion in all phases. For quantitative analysis we calculated signal intensity ratio, lesion-to-liver contrast ratio and liver parenchyma signal intensity gain on hepatobiliary phase. Statistical analysis was performed with the Wilcoxon sign-rank test for clustered paired data and the McNemar test for paired frequencies. A P value < 0.05 was considered statistically significant. RESULTS: At qualitative analysis no statistically significant differences were evident during any of the contrast-enhanced phases. Signal intensity ratio (P = 0.048), lesion-to-liver contrast ratio (P = 0.032) and liver parenchyma signal intensity gain (P = 0.012) were significantly higher on hepatobiliary phase after gadoxetate disodium injection. CONCLUSION: There were no significant differences in the MRI findings of focal nodular hyperplasia after the injection of a weight-based dose of either gadobenate dimeglumine or gadoxetate disodium.

yearjournalcountryeditionlanguage
2019-03-13
10.5152/dir.2019.18165http://hdl.handle.net/10447/350703